Study Name:
A Study of V940 Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer
Targeted Disease(s):
Lung Cancer
Purpose of Study:
The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement [N2]) non-small cell lung cancer (NSCLC).
Study Dates:
December 6, 2023 - June 25, 2030
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Funding Source:
Industry
Sponsors:
Merck Sharp & Dohme LLC
Contact:
Phone: 1-888-577-8839
Email: [email protected]
ClinicalTrails.gov Identifier:
NCT06077760
